Skip to main content

Table 1 Patient baseline clinical characteristics

From: Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis

Characteristics   All patients
N   18
Age Years 67.5 (48–84)
Sex, male n (%) 14 (77.8)
Duration of hemodialysis Years 2.7 (0.3–30)
Etiology of end-stage renal disease n (%)  
 Diabetic nephropathy   9 (50.0)
 Hypertensive kidney disease   5 (27.8)
 Glomerulonephritis   2 (11.1)
 Others   2 (11.1)
Weight kg 65.5 (46.0–81.5)
HCV genotype n (%)  
 1b   9 (50.0)
 2a   6 (33.3)
 2b   3 (16.7)
HCV treatment history n (%)  
 Naïve   14 (77.8)
 Interferon-based therapy   3 (18.8)
 Interferon-free therapy: daclatasvir and asunaprevir   3 (18.8)
Liver cirrhosis n (%) 4 (22.2)
Serum HCV-RNA levels Log10IU/ml 6.55 (4.1–7.3)
Baseline polymorphisms n (%)  
 NS3/4 only   0
 NS5A only   0
 Both NS3 and NS5A   3 (16.7)
Laboratory data
 Hemoglobin g/dL 11.8 (9.9–14.5)
 White blood cell /μl 5650 (3300–8000)
 Platelets × 104/μl 17.4 (6.2–27.8)
 Aspartate aminotransferase IU/L 20 (9–162)
 Alanine aminotransferase IU/L 16 (5.0–168)
 Total protein g/dL 7.3 (6.0–8.7)
 Serum albumin g/dL 4.0 (2.4–4.5)
 Blood urea nitrogen mg/dL 41.0 (19.9–63.0)
 Creatinine mg/dL 8.6 (4.4–13.0)
 Total bilirubin mg/dL 0.4 (0.2–0.9)
 Hemoglobin A1c % 5.7 (4.3–8.8)
 Alpha-fetoprotein ng/ml 2.0 (1–4.8)
 M2BPGi C.O.I 1.9 (0.52–19)
  1. Data are expressed as median, n (%), min-max
  2. RNA ribonucleic acid, M2BPGi Mac-2 binding protein glycan isomer